Skip to main content
. 2019 Apr 19;37(16):1380–1390. doi: 10.1200/JCO.18.01568

FIG 4.

FIG 4.

Progression-free survival (PFS) of participants with stage II/III with no gross residual disease. There were 870 participants with stage II or III and no gross residual disease documented at the completion of surgery of whom 534 (61%) experienced disease progression or death. Adjusted HR (95% CI) of PFS for intraperitoneal (IP) carboplatin vs. intravenous (IV) carboplatin = 0.92 (0.75 – 1.13). Adjusted HR (95% CI) of PFS for IP cisplatin vs. IV carboplatin = 0.97 (0.79 – 1.19). There was no statistically significant difference in PFS between the IV regimen and either of the IP regimens in this subgroup of patients.